文献速递鼻科

重度未控制慢性鼻窦炎伴鼻息肉患者生物制剂应答者:一项多中心观察性真实世界研究

Responders to biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: a multicentric observational real-life study.
PubMed 文献 · Rhinology · 2025-01-01

这项多中心18个月随访研究纳入326例开始生物制剂治疗的重度未控制慢性鼻窦炎伴鼻息肉成人患者,随访至18个月。SNOT-22中位评分从基线60.5降至3个月26.0,6个月时59%患者按EUFOREA-EPOS 2023标准为极佳应答者;多变量分析提示基线血嗜酸性粒细胞计数和生物制剂类型与6个月极佳应答存在提示性关联。

要点

  • SNOT-22中位评分从基线60.5降至3个月26.0。
  • 6个月时59%患者按EUFOREA-EPOS 2023标准为极佳应答者。
  • 基线血嗜酸性粒细胞计数和生物制剂类型与6个月极佳应答存在提示性关联。

核心结论

  • 这项真实世界研究证实生物制剂作为重度未控制慢性鼻窦炎伴鼻息肉患者的附加治疗有效。
  • 生物制剂可带来临床症状快速且持续的改善。
  • 相当比例患者表现出极佳应答,且无需全身性糖皮质激素。

研究设计与样本

  • 多中心18个月随访研究,纳入326例开始生物制剂治疗的重度未控制慢性鼻窦炎伴鼻息肉成人患者。
  • 在基线和随访3、6、12、18个月收集患者特征,包括临床和炎症标志物及合并症。
  • 基于现行指南考察成功率,并识别与6个月临床应答相关的潜在因素。

主要发现

  • SNOT-22中位评分(四分位距)从基线60.5(47-74)显著降至3个月26.0(11-41)。
  • 3个月时鼻症状和鼻内镜鼻息肉评分显著下降。
  • 生物制剂治疗6个月后,59%患者按EUFOREA-EPOS 2023标准被归类为极佳应答者。
  • 多变量分析显示基线血嗜酸性粒细胞计数、生物制剂类型与6个月极佳应答之间存在提示性关联。

关键数值与推荐

  • 采用EUFOREA-EPOS 2023标准判定极佳应答,6个月时59%患者为极佳应答者。
  • SNOT-22中位评分从基线60.5(47-74)降至3个月26.0(11-41)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials have demonstrated the effectiveness of biologics in treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, real-world evidence regarding patient outcomes and predictors of clinical response remains limited. METHODOLOGY: In this multicentric 18-month follow-up study, 326 adult patients who initiated biologic therapy for severe uncontrolled CRSwNP were included. Patient characteristics, including clinical and inflammatory markers, and comorbidities were collected at baseline and at 3, 6, 12, and 18 months of follow-up. We examined success rates based on current guidelines and identified potential factors associated to clinical response at 6 months. RESULTS: We observed a significant decrease of Sino-Nasal Outcomes Test-22 (SNOT-22) from a median score (interquartile range) of 60.5 (47-74) at baseline to 26.0 (11-41) at 3 months. A significant decrease of nasal symptoms and endoscopic nasal polyp score was observed at 3 months. After 6 months of biologic treatment, 59% of patients were classified as excellent responders according to the EUFOREA-EPOS 2023 criteria. Multivariate analysis revealed a suggestive association between baseline eosinophil blood count, type of biologic and an excellent response at 6 months. CONCLUSIONS: This real-world study confirms the effectiveness of biologics as an add-on therapy in patients with severe uncontrolled CRSwNP. Biologics lead to rapid and sustained improvement in clinical symptoms. A significant proportion of patients exhibit an excellent response, with no need for systemic corticosteroids.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Mortuaire G, Bequignon E, Daveau C, et al. Responders to biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: a multicentric observational real-life study. Rhinology. 2025. PMID: 39660730. doi:10.4193/Rhin24.284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。